Stergiou said the delayed timeline for reaching the final event trigger has increased optimism for the Regal trial. ・The CEO also disclosed that some Regal patients remain on treatment more than three ...

Investigators evaluated children with acute lymphoblastic or acute myeloid leukemia to identify racial/ethnic and neighborhood disparities in acute kidney injury.

Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while ...

Panelists discuss how the treatment landscape has evolved from limited options to include hypomethylating agents and venetoclax combinations, with emerging oral formulations promising greater ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Moleculin Biotech ( (MBRX)) has ...

The FDA has approved an oral combination therapy for certain adults with newly diagnosed acute myeloid leukemia.Decitabine ...

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AMLCAMBRIDGE, ...

A study revealed that RBPMS supports leukemia cell survival and progression. The protein upregulates FOXO1, leading to ...

Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunctionData ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

Other institutions, including Mariner and Ameritas Investment Partners, also increased exposure to the stock. ・Sellas said on Tuesday that its Phase 3 Regal AML study had reached 78 events as of May ...

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...